154 related articles for article (PubMed ID: 36993160)
1. Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS
Orsburn BC
bioRxiv; 2023 Sep; ():. PubMed ID: 36993160
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS
Orsburn BC
J Proteome Res; 2023 Dec; 22(12):3703-3713. PubMed ID: 37983312
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract][Full Text] [Related]
4. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
7. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Kras
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Sugimoto H; Arian KA; Ying H; Barekatain Y; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
bioRxiv; 2023 Feb; ():. PubMed ID: 36824971
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS
Ji X; Li Y; Kong X; Chen D; Lu J
ACS Omega; 2023 Feb; 8(7):7211-7221. PubMed ID: 36844555
[TBL] [Abstract][Full Text] [Related]
10. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
11. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura SF; Khan HY; Azmi AS
Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
[TBL] [Abstract][Full Text] [Related]
12. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of a small-molecule inhibitor of KRAS
Vázquez-Borrego MC; Granados-Rodríguez M; Bura FI; Martínez-López A; Rufián-Andújar B; Valenzuela-Molina F; Rodríguez-Ortiz L; Haro-Yuste S; Moreno-Serrano A; Ortega-Salas R; Pineda-Reyes R; Michán C; Alhama J; Romero-Ruiz A; Arjona-Sánchez Á
Exp Hematol Oncol; 2023 Dec; 12(1):102. PubMed ID: 38066554
[TBL] [Abstract][Full Text] [Related]
14. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologically targeting KRAS
Kumarasamy V; Frangou C; Wang J; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
bioRxiv; 2023 Apr; ():. PubMed ID: 37162905
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
17. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
18. KRAS inhibitors: going noncovalent.
Drosten M; Barbacid M
Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
[TBL] [Abstract][Full Text] [Related]
19. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
20. Mutation-Specific and Common Phosphotyrosine Signatures of
Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
[No Abstract] [Full Text] [Related]
[Next] [New Search]